Correlation Between Alnylam Pharmaceuticals and Apellis Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Alnylam Pharmaceuticals and Apellis Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alnylam Pharmaceuticals and Apellis Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Alnylam Pharmaceuticals and Apellis Pharmaceuticals, you can compare the effects of market volatilities on Alnylam Pharmaceuticals and Apellis Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alnylam Pharmaceuticals with a short position of Apellis Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alnylam Pharmaceuticals and Apellis Pharmaceuticals.
Diversification Opportunities for Alnylam Pharmaceuticals and Apellis Pharmaceuticals
-0.23 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Alnylam and Apellis is -0.23. Overlapping area represents the amount of risk that can be diversified away by holding Alnylam Pharmaceuticals and Apellis Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Apellis Pharmaceuticals and Alnylam Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alnylam Pharmaceuticals are associated (or correlated) with Apellis Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Apellis Pharmaceuticals has no effect on the direction of Alnylam Pharmaceuticals i.e., Alnylam Pharmaceuticals and Apellis Pharmaceuticals go up and down completely randomly.
Pair Corralation between Alnylam Pharmaceuticals and Apellis Pharmaceuticals
Given the investment horizon of 90 days Alnylam Pharmaceuticals is expected to under-perform the Apellis Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Alnylam Pharmaceuticals is 1.36 times less risky than Apellis Pharmaceuticals. The stock trades about -0.19 of its potential returns per unit of risk. The Apellis Pharmaceuticals is currently generating about 0.19 of returns per unit of risk over similar time horizon. If you would invest 2,734 in Apellis Pharmaceuticals on August 28, 2024 and sell it today you would earn a total of 457.00 from holding Apellis Pharmaceuticals or generate 16.72% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Alnylam Pharmaceuticals vs. Apellis Pharmaceuticals
Performance |
| Timeline |
| Alnylam Pharmaceuticals |
| Apellis Pharmaceuticals |
Alnylam Pharmaceuticals and Apellis Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Alnylam Pharmaceuticals and Apellis Pharmaceuticals
The main advantage of trading using opposite Alnylam Pharmaceuticals and Apellis Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alnylam Pharmaceuticals position performs unexpectedly, Apellis Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will offset losses from the drop in Apellis Pharmaceuticals' long position.| Alnylam Pharmaceuticals vs. ProQR Therapeutics BV | Alnylam Pharmaceuticals vs. Wave Life Sciences | Alnylam Pharmaceuticals vs. Blueprint Medicines Corp | Alnylam Pharmaceuticals vs. Apellis Pharmaceuticals |
| Apellis Pharmaceuticals vs. Eliem Therapeutics | Apellis Pharmaceuticals vs. HCW Biologics | Apellis Pharmaceuticals vs. Scpharmaceuticals | Apellis Pharmaceuticals vs. Milestone Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Complementary Tools
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |